Jastreboff and colleagues (NEJM, 2023) reported substantial body-weight reduction in obesity research populations, and Rosenstock and colleagues (Lancet, 2023) documented glycemic and weight effects in type-2 diabetes research populations
We have data in mice that suggest that things are not as straightforward as they might seem. The results appear in Cell Metabolism
Generally, Semaglutide is prescribed for adults with a Body Mass Index (BMI) of 30 or greater (obesity), or a BMI of 27 or greater (overweight) who also have at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol
Semaglutide/Wegovy is our most popular weight loss medication and is the gold standard for medical weight loss medications
It includes (1) a data-supported analysis of the existing situation / initial situation (development and structure of the population including the household structure and forecasts, existing healthcare provision and forecasts), (2) a dynamic, intermodal accessibility analysis of healthcare facilities, (Stiewing et al
Further evidence from a case report of bilateral NAION following weight loss on semaglutide illustrates how nonarteritic anterior ischemic optic neuropathy appears in real-world use
